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of intra-procedural thrombotic events (IPTE) on subsequent ischemic events.
Methods: 3428 patients who underwent PCI for non ST-segment elevation ACS in the
ACUITY trial underwent detailed frame-by-frame core lab angiographic analysis. An
IPTE was defined as the development of new or increasing thrombus, abrupt vessel
closure, no reflow, slow reflow, or distal embolization at any time during the procedure.
Results: A total of 121 patients (3.5%) had an IPTE. Patients with IPTE less frequently
had diabetes, hypertension, hyperlipidemia, or previous PCI, and more often had
elevated baseline cardiac biomarkers. Patients with IPTE were less often on a statin,
beta-blocker or angiotensin converting enzyme (ACE) inhibitor. Patients with an IPTE
had higher in-hospital, 30-day and 1-year rates of adjudicated MACE (death, MI, or
unplanned revascularization for ischemia) than patients without IPTE (25.6% vs. 6.3%
in-hospital, 30.6% vs. 9.3% at 30 days, and 37.0% vs. 20.5% at 1 year, p<0.0001 for
each). IPTE was strongly associated with Q-wave MI (in-hospital 6.6% vs. 0.5%, 30-
day 7.5% vs. 0.9%, and 1-year 8.5% vs. 1.5%, p<0.0001 for each), and out of lab
definite/probable stent thrombosis (in-hospital 3.3% vs. 0.5%, p=0.006; 30-day 5.8%
vs. 1.3%, p<0.0001; and 1-year 6.7% vs. 2.0%, p=0.0002). Unplanned
revascularization, target vessel revascularization, and non-CABG major bleeding were
also increased in patients with IPTE, as wasoverall 30-day mortality (3.3% vs. 0.7%,
P=0.002). Bymultivariable analyses, IPTE was independently associated with 30-day
and 1-year composite death/MI, definite/probable stent thrombosis, and composite
MACE.
Conclusion: The occurrence of IPTE in patients treated with PCI for ACS, while
relatively uncommon, is strongly associated with subsequent adverse ischemic
outcomes including death, MI and stent thrombosis.
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Background: In patients with ST-segment elevation myocardial infarction (STEMI),
timely reperfusion with primary percutaneous coronary intervention (PPCI) is the
preferred treatment. However, it remains unclear whether the optimal strategy is
complete revascularization or culprit vessel PPCI only.
Methods: From January 1, 2002 to June 25, 2009 all patients presenting with STEMI
treated with PPCI were identified from the Western Denmark Heart Registry, which
serves a population of 3.0 million. We examined mortality according to the timing of
multi-vessel PCI, i.e., acute procedure, staged procedure during the index
hospitalization, or procedure performed within 60 days after the discharge from the
index hospitalization. We compared mortality among patients with multi-vessel PPCI
with that among patients with single-vessel disease (SVD). The hazard ratio (HR) for
death was estimated using a time-dependent Cox regression model, with time of PCI
for the non-culprit lesion as the time-dependent variable.
Results: The study cohort consisted of 5,944 patients, of whom 4,770 (80%) had SVD
and 1,174 (20%) had multi-vessel PCI (MV-PCI) within 60 days. Among patients with
SVD and those with MV-PCI, one-year mortality was 4.9% (n=235) and 4.4% (n=52),
respectively. Among 354 (30.2%) patients with acute MV-PCI, 194 (16.5%) patients
with MV-PCI during the index hospitalization, and 626 (53.3%) patients with MV-PCI
within 60 days after the index hospitalization, the adjusted HRs for one-year mortality
were 1.53 (95% confidence interval (CI): 1.07-2.18), 0.60 (95% CI: 0.28-1.26), and
0.28 (95% CI: 0.14-0.54), respectively, compared to patients with SVD.
Conclusion: Acute MV-PCI in patients with STEMI was associated with increased
mortality compared to patients with SVD. Patients with multi-vessel diseased staged
for complete revascularization during the index hospitalization or within 60 days of
hospital discharge had mortality comparable to patients with SVD.
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Background: Everolimus-eluting stents (EES) have been shown to improve outcome
compared to paclitaxel-eluting stents (PES) in clinical trials. However, limited data are
available comparing second-generation EES with first-generation paclitaxel- and
sirolimus-eluting stents (SES) in real-life practice.
Methods: Analyses were performed on a pooled population of 3 contemporary
randomized trials in the Netherlands. The XAMI trial compared EES and SES in a
wide range of myocardial infarction (MI) patients. The COMPARE trial and
APPENDIX-AMI trial compared EES and either PES or SES in all-comers.
Results: A total of 3408 patients were randomly assigned to EES (53.0%), SES
(20.5%) or PES (26.5%). The groups were well matched in age and sex. However, the
proportion of interventions for acute MI differed between stents (41.1% in EES, 39.7%
in SES and 23.6% in PES, p<0.001). Furthermore, patients in the PES arm were more
likely to suffer from diabetes and hypertension. The unadjusted one-year outcome
showed a comparable incidence of all-cause death between stents (2.5% in EES, 2.8%
in SES and 1.7% in PES, p=0.300). MI occurred in 1.7% of EES patients compared to
0.9% in SES and 5.3% in PES (p<0.001). Target vessel revascularization (TVR) was
more frequent in PES patients (6.0% vs. 2.9% in EES and 3.8% in SES, p<0.001).
Furthermore, the composite end point of MACE (all-cause death, MI and TVR)
occurred more frequently in the PES group (9.1% vs. 6.2% in EES and 6.9% in SES,
p=0.024). Definite stent thrombosis was seen in 2.0% of PES patients, with rates of
0.3% in EES and 0.5% in SES (p<0.001). After multivariate analysis, use of PES was
found to be a predictor of MACE (OR 1.58, 95% CI 1.16-2.16).
Conclusion: In this pooled analysis of real-life practice trials, unadjusted one-year
outcomes were favorable for EES and SES compared to PES. After correction for
baseline differences, PES implantation was found to be an independent predictor of
MACE.
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Background: The safety and performance of the ABSORB™ Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Following this trial, ABSORB EXTEND was initiated as a global continued
access study (outside of the US) to expand experience with the ABSORB BVS to a
larger population of patients with complex lesions, including patients treated for longer
lesions using planned overlap of the ABSORB BVS. As part of the ABSORB EXTEND
study, a 50 patient imaging sub-study is being conducted with the aim of assessing the
outcomes of planned overlapping ABSORB BVS in the treatment of longer lesions.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients
with lesions ≤ 28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as
assessed by on-line QCA). Treatment of target lesion(s) can be conducted using
planned overlap of two ABSORB BVS of 18mm in length. A subset of up to 50 patients
who receive planned overlapping ABSORB BVS will be assessed using OCT,
angiography, and IVUS both post-procedure and at 2 years, in addition to their regular
clinical follow-up.
Results: This report represents the initial findings from patients who have had
implantation of overlapping ABSORB BVS in ABSORB EXTEND. Preliminary
experience with overlapping ABSORB BVS will be reported based on post-procedure
imaging (QCA and OCT) for those patients who are enrolled in the OCT subgroup.
Furthermore, preliminary clinical outcomes in patients receiving overlapping scaffolds
will be presented.
Conclusion: Clinical and imaging outcomes from the First-in-Man ABSORB trial have
demonstrated the safety and efficacy of the ABSORB BVS in lesions ≤ 14 mm.
Preliminary outcomes in patients receiving overlapping BVS from ABSORB EXTEND
will provide information on the feasibility of longer lesion treatment (≤ 28 mm) using
planned overlap of the ABSORB BVS.
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Background: The XIENCE V USA study is a large, prospective, multicenter, FDA-
required post-approval study designed to examine the safety and effectiveness of the
XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V, Abbott Vascular,
Santa Clara) in real-world clinical settings.
Methods: Clinical events, including stent thrombosis (ST), cardiac death and MI, target
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lesion failure and TLR, were adjudicated per ARC definition by an independent
Clinical Events Committee. Demographic, clinical, and procedural variables were
assessed using multivariable, stepwise, Cox regression analysis with independent
variables entered into the model at the 0.05 significance level. A time-dependent
covariate was used to assess the association between dual antiplatelet therapy (DAPT)
interruption and subsequent ST occurrence.
Results: There are two enrollment phases in this study with a total of 8061 patients,
including ~ 61% off-label patients. The 1-year clinical outcomes and their independent
predictors are shown in the table. About 80% of patients were treated with DAPT at 1
year.
1 Target lesion failure = cardiac death, MI (per ARC) attributed to target vessel and
clinically-indicated TLR.
Conclusion: In this large, complex, real-world population, XIENCE V demonstrated
low event rates at 1 year. In addition to clinical and lesion related variables, the
multivariate analysis revealed that premature DAPT interruption within 30 days was
an independent predictor of ST with the highest hazard ratio. However, DAPT
interruption after 30 days was not associated with subsequent ST.
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Background: RESOLUTE first-in-man (FIM) was the first study to evaluate the
Resolute zotarolimus-eluting stent (R-ZES, Medtronic, Inc, Santa Rosa, CA) in 130
patients treated for a single de novo lesion ≥ 14 mm and ≤ 27 mm in length, with a
reference vessel diameter of ≥ 2.5 mm and ≤ 3.5 mm. The R-ZES comprises a cobalt-
alloy, thin strut, metal stent; and a biocompatible polymer that allows prolonged drug
elution; with 85% eluted within the first 60 days, and the remaining exhausted by 180
days. The RESOLUTE FIM study is part of the global RESOLUTE Clinical Trial
Program, which comprises at least 5 trials specifically designed with consistent
endpoint definitions; standardized data collection, analysis and adjudication methods
to promote poolability. To date, the R-ZES has been studied in over 5000 patients; at
over 200 investigational sites worldwide.
Methods: Patients were enrolled from December 6, 2005 through June 9, 2006 at 12
centers in Australia and New Zealand. The primary endpoint was in-stent late loss at
9 months. The final 5-year follow-up outcomes will be reported.
Results: Baseline patient clinical characteristics include hyperlipidemia (94.6%),
hypertension (67.7%), prior MI (45.7%), unstable angina (29.7%), and diabetes
(17.7%). Of 131 lesions treated (2 lesions in 1 patient), mean length was 15.49±6.23
mm, 82% were B2/C, and 46.2% of patients had multivessel disease. At 4 years, the
cumulative incidence of TLR was 2.3%, TVF was 10.1%, MACE was 14.0%; without
any ARC definite and probable ST events at 4 years follow-up. At 4 years, 33.9% of
patients were still on dual antiplatelet therapy.
Conclusion: The R-ZES has shown long-term effectiveness and safety in a relatively
simple patient cohort through 4-year follow-up with a TLR rate of 2.3% and an ARC
definite and probable ST rate of 0.0%. We plan to report the final, 5-year clinical
outcomes in November, 2011 at the annual meeting of Transcatheter Cardiovascular
Therapeutics.
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Background: The XIENCE V everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) demonstrated superior efficacy and long term safety in the SPIRIT clinical
trials series. The next generation XIENCE PRIME EES includes 2.25 mm diameters
and 33 and 38 mm lengths to treat small vessels and long lesions (LL). The SPIRIT
PRIME trial aimed to show clinical equivalence of the XIENCE PRIME and XIENCE
V stents.
Methods: SPIRIT PRIME, a prospective, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME core sizes and LL (33 and 38 mm) stents.
The primary endpoint is 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data
according to FDA requirements. The Core Size Registry (CSR) analyzed 401 patients
and the Long Lesion Registry (LLR) 104 patients. Treatment of up to 2 de novo lesions
in different epicardial vessels was allowed. Data were fully monitored and all endpoint
events adjudicated by an independent committee.
Results: There were 447 CSR and 124 LLR lesions treated and a total of 530 XIENCE
PRIME and 105 XIENCE PRIME LL stents implanted. Clinical device success rates
were 98.2% (CSR) and 97.6% (LLR). Female and diabetic subjects were 29.7% and
34.9%, respectively in the CSR and 37.5% and 35.6%, respectively in the LLR. In both
arms, the primary endpoint was met by all analyses. The Table shows 1-year outcomes.
Conclusion: The SPIRIT PRIME study demonstrated 1-year safety and efficacy of the
new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in core size
and LL cohorts, suggesting clinical equivalence of the XIENCE PRIME stent to
XIENCE V.
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